Incyte and Merus enter Biclonics bispecific antibody collaboration
Incyte Corp. licensed exclusive rights to up to 11 therapeutic antibodies identified and developed with Merus NV’s Biclonics bispecific antibody discovery platform, including two (undisclosed) preclinical immuno-oncology candidates.
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.